Tag: years

Posted on

50 years ago: Lakers win record-setting 33rd game in a row

The night started with the Christmas carol “It Came Upon the Midnight Clear” playing while a packed crowd at the Forum in Inglewood nervously wondered if they’d get to watch history happen.

Games in mid-December during the marathon of an NBA calendar rarely have stakes like this. But if the Lakers could win — something they had done 20 consecutive times before — they’d celebrate on the court with a ceremony and in the locker room with champagne.

1971-72 Los Angeles Lakers team photo at the Forum

1971-72 Los Angeles Lakers team photo at the Forum

(Los Angeles Lakers)

On Sunday, Dec. 12, 1971, the Lakers won their 21st consecutive game, setting the record for the longest winning streak in NBA history.

“I’m sure glad it’s over,” Wilt Chamberlain said that night.

Yet the Lakers’ winning streak wasn’t close to ending. And the record they set — the longest winning streak in team sports — is still standing 50 years later.

The Lakers would win 33 straight games, an unfathomable achievement that spanned the course of 65 days during the team’s magical championship season, the franchise’s first after relocating from Minneapolis in 1960.

Lakers guard Jerry West (14) is fouled as he tries to get around Rockets guard John Vallely.

Lakers guard Jerry West (14) is fouled by Rockets guard John Vallely after driving around a screen by center Wilt Chamberlain on Dec. 27, 1971.

(Associated Press)

The Lakers scored 4,069 points during the streak, beating their opponents by an average of 16 points per game. Only one team, the Phoenix Suns, took them to overtime. And 24 times, opponents couldn’t keep the margin inside 10 points.

Chamberlain, Jerry West, Gail Goodrich, Pat Riley and Bill Sharman — the names on their own are legendary. But as part of the 1971-72 Lakers, they combined to create an accomplishment that’s still standing strong thanks to a combination of excellence, talent, time and place.

“If that 33-game winning streak at the time happened today with all the social media and coverage,” Riley, a backup guard on the team, told The Times, “it would be probably be almost unbearable to do.”

Riley should know. The Miami Heat team he helped assemble, with LeBron James and Chris Bosh joining Dwyane Wade, ripped off 27 consecutive wins in 2013. The Golden State Warriors pushed up against the fringes of the Lakers’ streak, winning 28 in a row over two regular seasons in 2015.

It hasn’t been close to being threatened since then.

“I’ll be honest. I don’t want to see it broken — at least during my lifetime,” said Jim Cleamons, a rookie on the Lakers’ 1971-72 team. “It’s like Joe DiMaggio. I don’t think anybody is going to beat his 56-game hitting streak, so I don’t want anybody to beat our 33-game winning streak. I’ll be honest about that. I don’t want to see it broken.

“I’m just sorry it wasn’t a little bit higher. I would have like to have really put it out there.”

All winning streaks before it and after it have started the same way — following a loss. But only the greatest streak in professional team sports could start with a loss like this.

Elgin Baylor wasn’t just a Laker at the time — he was the Lakers. He followed the team to Los Angeles from Minneapolis, bringing with him an electrifying style of play that would be mimicked by the NBA’s most exciting players for generations to come.

Lakers coach Bill Sharman yells instruction from the bench during the 1971-72 season.

Lakers coach Bill Sharman yells instruction from the bench during the 1971-72 season.

(Art Rogers / Los Angeles Times)

That version of Baylor was gone, an Achilles injury and achy knees slowing the Lakers’ most dynamic player to a crawl. Sharman, the Lakers’ new coach, wanted to make a change and move the 37-year-old Baylor out of the starting lineup.

Baylor, having played in only nine games before the winning streak began, instead retired. He made the decision after the Lakers lost to the Golden State Warriors by four points on Oct. 31, 1971.

“He was not getting the kind of results that he expected of himself,” Goodrich said. “When you’re that good — boy, he was that good — and you start to see your skills diminished a little bit. … And while you can still make a contribution, I think that, you know, his benchmark was so high for himself.”

It was hard to fathom, especially for West.

“My buddy, my friend, my cohort for so many years, I just sat there and said to myself, ‘How the hell is this going to be without him in the locker room?’ ” West remembered wondering. “It just was a shock for me. I had no clue, absolutely no clue that he was going to retire. None. I said, ‘What?’ when I heard about it. … How did this happen? Why?

“That’s why it was so shocking for him not to be there. But as I say, they don’t cancel school when a teacher leaves. So, they’re certainly not cancelling a basketball season, that’s for sure.”

For Sharman, it wasn’t the first time the team’s coach was in the midst of a challenge. Before he lost Baylor, he needed to first convince West to shoot less and distribute the ball more. Admittedly, that sell was easier than the other one he needed to make.

He needed to convince Chamberlain to wake up early.

Sharman was the inventor of the “shootaround” — a morning practice on game days designed to increase players muscle memory and focus before competition. It also meant an extra trip to the arena, with Chamberlain firing back that Sharman would see him at the Forum once per day — either for practice or the game.

Like the best jokes, it was full of truth.

But Sharman had Chamberlain’s respect from his time as Bob Cousy’s backcourt partner during the Boston Celtics’ dynasty. Sharman believed in work ethic, a tone he set during the team’s training camp in Hawaii.

After a lunch with Chamberlain, he got the Lakers center on board.

Like West, he also convinced Chamberlain — owner of another iconic record, his 100-point game — to sacrifice on offense to anchor the Lakers’ defense and rebounding, while playing quarterback for Sharman’s fast-break offense.

After Baylor’s retirement, Sharman turned to West and Chamberlain to be the team’s co-captains. West felt he’d play better without the responsibility, so Chamberlain took on the task alone, he wrote in his autobiography, “Wilt: Just like any other 7-foot black millionaire who lives next door.”

With Chamberlain as the captain and young Jim McMillian replacing Baylor in the starting lineup, the Lakers eased into their new reality with a tight win at home against the Baltimore Bullets.

“McMillian stepped in. He fit right in — a good quality scorer, a very, very good defensive player,” Goodrich said. “And so, at that point, you know, there was there was no drop off. And we were off.”

They wouldn’t lose again for more than two months.

Legendary Lakers broadcaster Chick Hearn narrated a record with highlights of the team’s 33 wins, praising the Lakers for catching their rhythm with a 40-point win in Philadelphia for their fifth consecutive victory.

“One of the best games in the history of the Lakers,” Hearn exclaimed that night.

If there were questions about Chamberlain’s buy-in to Sharman’s plan, he answered them against the Boston Celtics, managing to dominate despite scoring only three points in two shots and one trip to the free-throw line.

Chamberlain finished that win — the Lakers’ eighth in a row — with 31 rebounds, 10 assists and, according to Hearn, 13 blocked shots for one of the strangest triple-doubles in NBA history.

“It was pretty to watch, I’ll say that. It was pretty to watch,” West remembered. “Everyone shared in different ways. And I’ll never forget that before the season started, Bill Sharman asked me, he said, ‘I want you to lead the league in assists.’ I said, ‘I’ll try, if I can.’

“After my knee injury, I wasn’t the same player at all. I think I averaged almost 26 points a game even that way. But these games were easy because you just didn’t feel the pressure to score all the time and it got easier for us. Everyone had a role and they performed it.”

West and Chamberlain were the veterans. Goodrich was the scorer. McMillian provided the two-way support. Happy Hairston was a rebounding machine. Flynn Robinson, the team’s sixth man, could really shoot, and Riley was equally fearless and ferocious. John Trapp and Leroy Ellis reveled in the dirty work.

The Lakers kept piling up wins, even more impressively considering of how differently the NBA was scheduled in 1971-72. The winning streak began with victories on three straight nights. The first five games of the 33 were played in six days. The first eight wins? That happened in 10 days. Add in commercial travel the morning following games, and the physical demands were incredible.

“I think that’s a pretty incredible stat that the a lot of people don’t realize,” Goodrich said.

They fell into routines, Goodrich leaving the court after the same made shot before every game and West playing in the same sneakers throughout the run.

By the time the Lakers hosted the Atlanta Hawks on Dec. 12, people certainly realized the stakes. A win would break the Milwaukee Bucks’ record of 20 straight wins during their championship run the season before, immortalizing Sharman’s team. The fans counted down the final seconds before the 21st win in the streak.

Lakers guard Gail Goodrich drives past 76ers guard Dave Wohl, who fell to the court after tripping over Wilt Chamberlain.

Lakers guard Gail Goodrich (25) and center Wilt Chamberlain (13) defeated guard Dave Wohl and the 76ers during their 33-game winning streak.

(Associated Press)

The postgame locker room was a wild scene, Hearn and partner Lynn Shackleford interviewing players while they celebrated.

“I believe this is the greatest thrill,” Sharman said.

Owner Jack Kent Cooke told Hearn he nearly suffered a heart attack as the Lakers desperately held on.

“But it was all worth it, wasn’t it?” he said to Hearn.

Ten days later in Baltimore, the Lakers got 37 points and nine assists from West to pass the 1916 New York Giants with 27 straight wins. Those Giants had won 26 without a loss, though there was a non-counting tie during their streak.

And in Atlanta on Jan. 7, the Lakers were as dominant as ever, making 58{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of their shots while six players scored in double figures in a blowout win against Pete Maravich and the Hawks.

It was the team’s 33rd win in a row.

Two days later in Milwaukee against the defending NBA champions, the Lakers would finally lose 120-104.

“We went into the locker room after the game and it was over with, the 33 wins a row,” Riley said. “We got on a plane.”

The season would end with another victory that ended another streak: The Lakers finally won an NBA championship after losing seven finals in the first 11 years since moving to L.A. But the memory of the 33-game win streak would always linger.

“Some 2½ months without losing a game,” West said. “Pretty remarkable.”

Posted on

Under Honda CEO’s radical vision, will company be recognizable in 20 years?

Mibe is convinced that Honda, as one of the world’s top producers of combustion engines and — as a result — of carbon emissions, has a social responsibility to refocus on carbon-neutral enterprises.

“That is the main aim,” Mibe said at Honda Innovation Lab Tokyo, which is housed in a downtown high-rise and works on connected, digital and artificial intelligence projects.

“I have a concrete image of beyond 2030 — the social structure will be changed, not only for automobiles but also for other areas,” he said. “The business model itself has to change.”

With his vision stretching some two decades into the future, Mibe won’t be around to see it to fruition. But outsiders say his ambitious revamp has reignited a spark of urgency and innovation at a company that still prides itself on engineering feats such as the CVCC engine.

“Honda’s mojo is coming back,” said Takaki Nakanishi, head auto analyst at Nakanishi Research Institute in Tokyo. “Whether Mibe can do it or not is one matter. But he has made the commitment to try. And that is what is different from other Japanese auto leaders.”

New partners

Sustaining Honda’s long-term viability is a top priority for Mibe.

The new boss took the wheel on April 1, and he is already easing away from the headstrong corporate independence that a parade of predecessors in the CEO office long deemed sacrosanct.

Honda is the only Japanese auto company still clinging to independence, as compatriot automakers coalesce into two blocs centered on Toyota and Nissan. But as a midsize player on the global stage, Honda needs the help of friends, Mibe concedes.

For the time being, that means cooperating with General Motors on a range of projects, from hydrogen fuel cell technology to electric vehicles. But whereas previous Honda heads adamantly ruled out corporate cross-shareholdings with GM or anyone else, Mibe said he is open to any partnership that brings value and a competitive edge — corporate ego be damned.

“I’m not simply hung up on maintaining independence,” he said. “It is not ‘independence first.’ ”

Mibe cited partnerships with information technology companies and even entertainment companies as ideas worth exploring as Honda seeks new businesses.

“If holding shares becomes necessary as part of that, then we would need to consider that, too,” Mibe said. “If we look at Honda now, can we do everything by ourselves? Unfortunately, the answer is no. So I will be considering the possibilities of an alliance or alliances.

“I must say I am already thinking about that,” he said. Honda is not in talks with Apple, Mibe said.

Posted on

Under Honda CEO Toshihiro Mibe’s radical vision, will company be recognizable in 20 years?

Mibe stated the grand approach is nevertheless having shape. But Honda may perhaps announce new particulars, this sort of as product and battery methods for North America, in early 2022, he claimed.

In China, Honda has now furnished a glimpse. In Oct, Mibe declared that Honda will introduce 10 EV products in China in the future five many years underneath a new “e:N Series” brand name. Honda even envisions exporting these types from China. To underscore its intentions, Honda showed three EV concept vehicles with angular styling, slablike sheet metal and sharp boatlike prows.

How significantly will the international EV overhaul charge?

“All I can say is billions and billions,” Mibe said.

Honda’s ramp-up will get off in the late 2020s, subsequent the arrival of solid-condition batteries. That technology will be a “sport-changer,” he reported.

In a feeling, Honda is refraining from massive investments in modern lithium ion battery know-how on the guess that the solid-point out breakthrough is suitable all over the corner.

Honda programs to make a pilot line for good-point out batteries in 2022 as a action towards mass creation, Mibe reported. In the meantime, Honda’s partnership with GM can be observed as a bridge to that period, serving to Honda fill the hole with EVs until its personal up coming-gen tech is all set.

“If we make way too substantial an financial commitment, we sense the production facilities can’t be easily commonized involving lithium ion and stable-point out batteries,” Mibe said. “So we need to have to imagine extensive phrase and assume about what timing is ideal for this financial investment of billions and billions.”

But a single thing Honda very likely will never detail at any time quickly is a prolonged-time period car or truck income goal.

Honda offered 4.55 million automobiles worldwide in the fiscal 12 months ended March 31, 2021, and expects deliveries to fall to 4.2 million in the recent fiscal yr as the worldwide semiconductor lack has an effect on output. The automaker wants 40 per cent of its income in significant marketplaces, these as North The usa, to be both whole-electric or fuel mobile cars in 2030, and the entire world fleet to be zero emissions in 2040.

But Mibe claims worth will hinge on new mobility designs and software, not always volume.

“In typical, the absolute variety of cars may drop because of sharing. I do not feel we can keep the absolute selection of vehicles out there,” Mibe stated of the industry’s course.

“We absolutely have to transform the present-day automobile business design alone,” he claimed. “That is why we are not publishing a numerical target. The profitability structure will change as nicely.”

Posted on

How insulin has changed diabetes care, 100 years on

This November, we celebrate 100 years since the discovery of insulin, the hormone that provides the key to understanding and treating diabetes. In this Special Feature and podcast, we look at how far insulin research has come, and we consider what its future may hold.

Insulin is the hormone that helps regulate blood sugar levels, keeping them at healthy concentrations. The pancreas is the organ that produces this hormone, which is normally released in quantities dependent on the levels of blood sugar present in the system at any one time.

People whose bodies are unable to regulate blood sugar levels have diabetes mellitus, which can be of two types, depending on why this regulation does not occur.

In type 1 diabetes, the body does not produce insulin, while in type 2 diabetes, it does not respond to the insulin produced and released by the pancreas.

Around the world, hundreds of millions of people live with a form of this chronic condition, and insulin treatments are key to its management, particularly to the extent that type 1 diabetes is concerned.

People with type 1 diabetes must take insulin, as their bodies do not produce it. Individuals with type 2 diabetes control their blood sugar levels typically through special medication and dietary and lifestyle interventions.

However, some may also require insulin treatment if the cells that produce insulin — called pancreatic beta cells — deteriorate in time and stop producing sufficient insulin.

In this Special Feature and associated “In Conversation” podcast, we offer an overview of the importance of insulin, its history, and what future research likely holds for insulin therapy and the management of diabetes.

To find out more about the impact of type 1 diabetes and the challenges of using insulin, we spoke to Virginie, a woman who received a diagnosis for this condition in her 30s.

For insights into current insulin research and potential future developments, we interviewed Dr. Thomas Barber, honorary consultant endocrinologist and assistant professor at the Warwick Medical School in the United Kingdom.

Diabetes was known — as a collection of symptoms — over 3,500 years ago, as a papyrus dating from 1550 before the common era (BCE) was already describing a condition consistent with the symptoms of diabetes.

Even though physicians have encountered and treated diabetes throughout history, researchers only discovered the reason behind it around 100 years ago: insulin, the hormone that regulates blood sugar levels.

In 1889, Joseph von Mering and Oskar Minkowski, two researchers at the University of Strasbourg in France, removed the pancreases of dogs and found that the animals would then go on to develop diabetes.

As we now know, the pancreas is the organ that produces insulin. However, von Mering and Minkowski were not able to establish this connection at the time.

It was a little over 30 years later, in 1921, that Sir Frederick Banting and Charles Best — working in the laboratory of John Macleod — from the University of Toronto in Canada extracted insulin from the hormone-producing cells found in the pancreases of healthy dogs.

They then injected dogs with diabetes with this “extract” and thereby made the discovery that changed the face of type 1 diabetes treatment forever.

In 1922, Banting and Best treated a young boy with type 1 diabetes by injecting him with insulin. This saved his life — at the time, type 1 diabetes became a terminal illness more often than not — and cemented the importance of the researchers’ discovery.

Banting and Macleod won the Nobel prize in medicine “for the discovery of insulin” in 1923.

In 1946, researchers discovered intermediate-acting insulin, also known as Neutral Protamine Hagedorn (NPH) insulin, which persists in the body for 14–24 hours, which means that people who take it require fewer injections. This is still one of the most widely used types of insulin to this day.

At present, however, NPH insulin is no longer extracted from animal sources. Instead, researchers synthesize artificial human NPH insulin in the lab.

At present, there are several different types of therapeutic insulin, and people may have taken one or several of these, depending on their individual needs.

These types are:

  • fast-acting insulin, which starts to take effect around 15 minutes after entering the body
  • short-acting or regular insulin, which takes effect around 30 minutes after entering the body
  • intermediate-acting insulin, which starts to work 2–4 hours after entering the body
  • long-acting insulin, which starts to work several hours after entering the body and has a longer effect

Depending on their needs and what is accessible to them, people may receive therapeutic insulin through:

  • syringe injections, the traditional delivery method
  • an insulin pen, which also injects insulin but is easier to use than a syringe
  • an insulin pump, which automates the process of insulin delivery throughout 14 hours

While the subcutaneous delivery of insulin may make it harder for some people to adhere to the correct treatment regimen, other delivery methods have so far proved unsuccessful.

For example, in the 1990s, some companies have also developed and attempted to commercialize insulin inhalers, which would deliver the hormone in aerosolized form.

However, these never took off, most likely because they are less effective than delivering insulin subcutaneously, as some of the insulin gets lost in the process.

So what does the future hold for insulin research and therapy? In some ways, we could say, the future is now, as people are already using smartphone technology to assist them in adhering to their treatments and determining how much insulin they need to use.

Today, individuals use mHealth technology — referring to the practice of healthcare supported by mobile smart devices — to help them monitor their blood sugar levels, so they know how much insulin to take. Glucose monitors are currently available — these are small sensors placed under the skin that pick up on variations in blood sugar levels.

These connect to a smart device and allow the person to read their blood sugar levels at any time and share them with a doctor in real-time.

Some fully automated insulin delivery systems are also available. These are called “closed-loop insulin systems,” also known as “artificial pancreases.” They work by transmitting real-time blood sugar level data to a smart device that then communicates with a person’s insulin pump, regulating how much insulin enters the system at any one time.

However, some challenges remain that future developments need to address. These include insufficiently accurate glucose monitoring devices, as well as concerns regarding user data collection. Current closed-loop systems also rely on user control, while researchers are yet to develop fully independently running artificial pancreases.

Dr. Barber noted that independently functioning artificial pancreases are akin to the “Holy Grail” of diabetes therapy.

“There is some fascinating research to suggest that [the independent artificial pancreas] can be done,” Dr. Barber told us.

“It’s been shown that can actually reduce hypoglycemic rates by having that kind of technology in place. But we’re some way away from actually being able to have an artificial pancreas, which doesn’t rely on the patient at all. And really, […] I think it will come, but we’re not quite there yet.”

– Dr. Thomas Barber

Another pathway for future research is gene therapy that would trigger the expression of insulin-producing cells, thereby tackling the cause of type 1 diabetes at the root. The research so far, while it has garnered some interest, has been in animal models, and scientists are yet to take this to the next step: clinical trials in humans.

Finally, scientists are also looking at ways of developing better insulin, and several areas of investigation appear to hold promise.

One option is developing glucose-responsive or “smart” insulin. One of the main challenges in treating type 1 diabetes and severe type 2 diabetes remains administering insulin doses that accurately “match” blood sugar levels.

If blood sugar levels become or remain too high, a person can experience hyperglycemia. This, in turn, can lead to various complications in the long term, such as eye problems or diabetic ketoacidosis.

Yet if a person takes too much insulin, they can develop hypoglycemia, where their blood sugar levels are too low. Its symptoms can include heart palpitations, dizziness, and blurred vision. It can also lead to further complications, such as seizures and loss of consciousness.

Smart insulin would help address the risk of hyperglycemia and hypoglycemia by responding to changes in a person’s blood sugar levels in a way that would mimic healthy insulin function.

Eliminating or attenuating insulin fibrillation and aggregation — a process that renders insulin manufacturing more difficult — would make it easier to produce and store insulin.

Another area of development looks at ultrarapid insulin, which starts acting sooner after delivery. It helps improve the management of fast changes in blood sugar from before to after a meal — a process known as “postprandial glucose excursions.”

Another issue that needs addressing in the near future is the lack of accurate and consistent information regarding both insulin therapy and the unexpected factors that can influence a person’s blood sugar levels, besides diet.

Virginie, for instance, wondered how much researchers and clinicians know about the relationship between anxiety and blood sugar levels and how this might affect people with diabetes who require insulin therapy.

In answer to her question, Dr. Barber explained that “glucose control is far more complex than simply what [a person’s] levels of insulin are, and indeed how much insulin you inject.”

“There’s actually 101 things [that] can influence blood sugar levels. And in fact, one of those is mental and emotional status at the time. And if you’re worried, or stressed, or anxious, that in itself can actually push your blood sugar levels up, because it’s associated with the release of the stress hormone cortisol and also the sympathetic response as well, which is the fight or flight adrenaline release, both of which act to raise your blood sugar levels.”

– Dr. Thomas Barber

This is one of the many reasons why it is so important for doctors to listen closely to the experiences of people living with diabetes.

“[W]hen I’m seeing patients in clinic, I’m acutely aware of the fact that they have far more insight into their own diabetes than I do,” Dr. Barber noted. “They’ve been living with this [condition] day after day, hour after hour, week, months, years, sometimes even decades. And I think it’s really important that as healthcare professionals, we’re aware of this and we respect that.”

Virginie further noted that anxiety regarding insulin treatments can also affect those living with diabetes in another way. Often, those around her are anxious about how the condition affects her and whether she has been able to take the correct insulin dose at the correct time.

Diabetes can also take a heavy toll on the friends and families of those with this condition, she pointed out.

Dr. Barber acknowledged the real human impact of a diabetes diagnosis and the serious lifestyle adjustments that come with having to undergo insulin therapy.

One of these is the necessity of self-injecting insulin, which, he said, causes anxiety in many patients. “And understandably, because of all of these factors, there’s often quite a lot of resistance to the idea of going on to [insulin] therapy,” he admitted.

The solution? Empathetic sensitive, and mental health-aware care, according to Dr. Barber:

“There is a relative lack of proper psychology and talking-based therapies for patients with diabetes, and one almost feels as if there’s a need for these patients not just to have the standard education on diabetes, but to have the focused psychological support, which is really a separate thing from education. I think they should have, obviously, the two together, but the psychological support is often lacking. And I think that really is an unmet need. And I think it’s something we could certainly do a lot more on in the future.”

Perhaps the greatest challenge going forward, however, is ensuring equitable access to appropriate care and education for the management of diabetes.

While this condition is common worldwide, it does not affect everyone in the same way, and not everyone has timely access to diagnosis and care.

Black, Hispanic, and American Indian individuals have a higher likelihood of developing diabetes compared with people of other races and ethnicities.

Yet, people from these groups face the highest rate of disparities in access to appropriate healthcare, often due to systemic racism and socioeconomic factors.

To this day, Dr. Barber told us, lack of access to insulin remains the number one cause of death among children with type 1 diabetes worldwide:

“Did you know that globally, the most common cause of death for a child living with type 1 diabetes is actually [the] lack of access to insulin? That’s an incredible fact. It’s a tragic fact. And it’s actually quite shameful that after 100 years of having insulin, [which the World Health Organization (WHO) classes] as an essential medication, that children around the world with type 1 diabetes are dying because they don’t have access to this therapy. Something needs to be done.”

However, solving the issue of inequitable access to insulin therapy, glucose monitoring systems, and even basic education about diabetes is going to be no mean feat, according to Dr. Barber.

“[I]t’s a hugely complex issue,” he pointed out. “It’s not just the case of providing insulin, […] there [are the] huge complexities of […] infrastructure, data collection, [taking] cultural differences [into account] and so on.”

Some initiatives do exist to address these disparities. One example is the 100 Campaign, “which is aiming to improve the situation for patients around the world to have access to insulin,” Dr. Barber told us. However, we are still a long way away from solving this problem.

Virginie emphatically expressed a hope that going forward, healthcare decision-makers will work to improve access to care, health education, and diagnosis for people living with diabetes.

“I think it’s very important that […] we make sure we provide the access for all […] not just […] to insulin, but access to the diagnosis, and to actually think about our own assumptions [about diabetes],” she told us.

“Certainly, I didn’t know that thrush could be a symptom of diabetes. I also had a foot drop, which I didn’t know could be a symptom. I was thirsty all the time. [Before my diagnosis,] I was drinking more than 6 liters [of liquid] per day and only stopping because I knew 6 liters — that’s a lot. […] So my hope is that […] any sort of worry and concern is taken seriously. […] It has taken a while for me to get the diagnosis, and we’re only talking months. So I’m thinking about people who have to wait for years for [a] diagnosis. And I think it’s really important that […] we consider that as well.”

– Virginie

Posted on

MS in adulthood linked to viral infections in teenage years

teenager checking phone seen from aboveShare on Pinterest
New investigate indicates that bacterial infections in teenage a long time may raise the risk of finding an MS prognosis as an grownup. jacoblund/Getty Pictures
  • Various sclerosis triggers may well come about decades prior to symptom onset and prognosis.
  • Serious infections in people’s teenage yrs may possibly boost their hazard of an MS prognosis later on in existence.
  • Infection plays a significant purpose no matter of genetic hazard.

Multiple sclerosis (MS) is an unpredictable disease of the central anxious system (CNS) that influences the mind and spinal wire. In accordance to the National Various Sclerosis Society, there had been practically 1 million grown ups living with MS in the United States in 2017, which is additional than twice the reported number in 1975.

The initial signs and symptoms of MS are normally vision-linked — these as double vision, blurred eyesight, pink-inexperienced coloration distortion — but the illness can influence practically any section of the overall body, depending on which elements of the CNS are weakened.

In addition to challenges with vision, common signs or symptoms involve issues with:

  • balance and muscle mass weakness
  • memory and contemplating
  • emotion
  • sensations of numbness, prickling, or “pins and needles”

There is now no overcome for MS, but quite a few distinctive treatments and therapies exist to take care of the indications and cut down how generally the indicators return.

A mix of environmental and genetic things appears to be responsible for MS, but the actual trigger of the disease is mysterious.

Researchers feel that it is an autoimmune condition. In individuals with MS, the immune method mistakenly assaults the myelin coating of the CNS.

Myelin protects the nerves and can help messages journey amongst the brain and the rest of the body. When the protecting coating will become harmed, it can gradual, change, or halt these messages.

The overall health file knowledge for various million men and women born in Sweden between 1970 and 1994 recommend that a variety of serious bacterial infections in adolescence may possibly be possibility things for MS prognosis in later on yrs.

The exploration, which features in Brain, observed that activities that lead to swelling of the CNS can raise the danger of MS diagnosis.

Glandular fever, which occurs thanks to the Epstein-Barr virus (EBV) and is also recognised as infectious mononucleosis (IM), showed the greatest association with MS analysis.

Tim Coetzee, Ph.D., who is main advocacy, solutions and investigate officer at the Nationwide MS Modern society and was not associated with the review, instructed Health-related News Right now, “The information […] increase to the growing body of information about the possible of EBV staying a prospective viral cause for MS.”

The study also located an amplified threat linked with other styles of an infection and head trauma in the teenage a long time.

The direct author of the examine is Prof. Scott Montgomery, scientific epidemiologist and director of the Clinical Epidemiology group at Örebro College and Örebro University hospital in Sweden. He instructed MNT that a person of the key challenges with exploring chance variables of the ailment is that they “may come about numerous years ahead of MS is diagnosed, as the disorder has an extended period of time of enhancement in advance of it is adequately symptomatic for a prognosis.”

A next analyze, which seems in JAMA Network Open, provides to the growing fascination in irrespective of whether viral infections in a person’s teenage a long time can result in MS at an more mature age.

For this review, which involved practically 2.5 million persons in Sweden, the scientists seemed at knowledge on medical center-identified IM in little ones aged up to 10 years and adolescents aged 11–19 years. They then as opposed this details towards MS diagnoses later in daily life. To understand the effects of relatives daily life — an environmental element — and genetics, the crew integrated siblings in the research.

Prof. Montgomery points out, “If one particular sibling develops glandular fever and goes on to build MS, when the other does not build glandular fever and does not establish MS, that would suggest that it is the glandular fever rather than any genetic predisposition that led to the MS.”

Through the research period, 5,867 men and women acquired a analysis of MS from the age of 20 yrs. In general, children and adolescents with clinic-diagnosed IM had a higher danger, but young people confirmed the best chance of subsequent MS diagnosis.

According to Prof. Montgomery, the get-household information of the research is that “infectious mononucleosis all through ages 11–15 years was typically affiliated with an MS diagnosis around age 30 a long time […]. The realization that adolescence is these an important time of susceptibility also focuses our perform.”

Dr. Coetzee explained to MNT:

“Understanding the risk elements and triggers for MS is of essential value to the MS community. These scientific studies highlight the relevance of cautiously discovering whether or not viral infections like EBV and other glandular fevers set somebody at higher possibility for acquiring MS.”

He stated, “We need to have experiments like this a person to pinpoint the aspects that add to the possibility of MS so that we can develop procedures to reduce the onset of MS.”

The review was restricted by the exclusion of IM diagnosis in principal care and outpatient options, which means that it integrated only the most extreme bacterial infections. Similarly, the authors observed that it was not attainable to detect the symptomatic onset of MS right before its diagnosis.

In response to a question about the next steps for the study, Prof. Montgomery stated, “We now acknowledge that adolescence seems to represent a period of heightened susceptibility to exposures that may perhaps consequence in MS.” The research crew is now “working to superior characterize the environmental exposures similar to MS chance […], investigating no matter if the various pitfalls are additive or if some modify the outcome of other folks.”

The influence of intense infection on the potential overall health of kids and teenagers is of growing value in gentle of the surge in the degrees of the SARS-CoV-2 virus circulating in youngsters. Could this lead to a wave in MS circumstances in the long term?

Dr. Coetzee thinks that it is too early to say. He said, “At this place, it would be premature to speculate about regardless of whether someone is at increased risk of MS […] — we never have sufficient details about the long-time period effects of SARS-COV-2 infection on individuals to make conclusions about an individual’s possibility of producing MS owing to a SARS-COV-2 infection.”

Posted on

Olivier Rousteing celebrates 10 years at Balmain